The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants

  • Years ago, in a conversation with an endocrinologist, I mentioned there was no incentive to cure diabetes, giving the money companies were making from managing it (with testing supplies, insulin, etc.). He replied that the incumbents had no incentive to cure it, but a startup company would.